Atorvastatin

Introduction Overview

Generic Name

atorvastatin

Brand Name

Lipitor

Dosage Form

oral tablet (10 mg; 20 mg; 40 mg; 80 mg)

Drug Class

Statins (HMG-CoA reductase inhibitors)

Pharmacokinetics

Absorption:
Atorvastatin is well absorbed orally with peak plasma concentrations typically reached within 1 to 2 hours after administration. Its absolute bioavailability is approximately 14%, primarily due to extensive first-pass metabolism in the liver. Food intake has minimal effect on the rate and extent of absorption, allowing flexible administration with or without meals. The drug exhibits linear pharmacokinetics over the therapeutic dose range, with no significant accumulation upon repeated dosing.

Distribution:
Atorvastatin is highly protein-bound in plasma (>98%), predominantly to albumin. It is extensively distributed to hepatic tissue, which is the primary site of its action. Volume of distribution ranges from approximately 381 liters, indicating wide tissue distribution. It crosses the placenta but is not significantly excreted into breast milk. Distribution to skeletal muscle has been noted, pertinent to potential muscle-related adverse effects.

Metabolism:
The drug undergoes extensive hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4) isoenzyme to active ortho- and para-hydroxylated derivatives, as well as various beta-oxidation metabolites. These metabolites retain lipid-lowering activity and contribute substantially to the therapeutic effect. Atorvastatin demonstrates a significant first-pass effect leading to reduced systemic availability but high intrahepatic concentrations.

Elimination:
Atorvastatin exhibits a biphasic elimination with an initial half-life of approximately 14 hours; however, the inhibitory activity on HMG-CoA reductase lasts 20 to 30 hours due to the active metabolites. It is eliminated primarily via biliary excretion, with less than 2% excreted unchanged in urine. Fecal excretion is the major route for both parent drug and metabolites. Renal impairment has limited effect on drug clearance, whereas hepatic impairment significantly alters metabolism and elimination, necessitating dose adjustments and monitoring.

Dosage Forms

Available Dosage Forms:
Lipitor is formulated as film-coated oral tablets available in strengths of 10 mg, 20 mg, 40 mg, and 80 mg. Tablets contain atorvastatin calcium as the active ingredient and various inactive ingredients including calcium carbonate, croscarmellose sodium, lactose monohydrate, and others to ensure stability and bioavailability.

Dosages for Adults and Adolescents:
In adults with hypercholesterolemia or mixed dyslipidemia, the starting dose typically ranges from 10 mg to 20 mg once daily, titrated up to a maximum of 80 mg daily based on therapeutic response and tolerability. For pediatric patients aged 10 to 17 years with familial heterozygous hypercholesterolemia, the recommended starting dose is 10 mg once daily, with titration up to 20 mg daily. Dose adjustments should be guided by lipid level monitoring every 4 weeks initially.

Specific Patient Populations:
In patients with hepatic impairment, Lipitor is contraindicated or used with extreme caution, avoiding initiation in active liver disease or unexplained persistent transaminase elevations. In elderly patients, no specific dose adjustments are typically required, but increased risk of adverse events mandates careful monitoring. Patients with renal impairment do not require dose alteration as renal elimination is minimal. Use in pregnancy and lactation is contraindicated due to potential teratogenicity. Dosage regimens must also consider potential drug interactions that may warrant dose modification.

Mechanism Of Action

Atorvastatin functions as a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway. By competitively inhibiting this enzyme, atorvastatin decreases the conversion of HMG-CoA to mevalonate, an essential early step in cholesterol synthesis.

This inhibition reduces intracellular cholesterol concentrations in hepatocytes, leading to upregulation of low-density lipoprotein (LDL) receptors on the cell surface. Enhanced LDL receptor expression increases the clearance of circulating LDL cholesterol, thereby lowering plasma LDL levels significantly. The reduction also diminishes very low-density lipoprotein (VLDL) and triglyceride synthesis.

Apart from lipid-lowering effects, atorvastatin exhibits pleiotropic actions, including improving endothelial function, stabilizing atherosclerotic plaques, reducing oxidative stress and inflammation, and inhibiting thrombus formation. These additional mechanisms contribute to its cardiovascular protective benefits beyond cholesterol reduction.

Comparatively, atorvastatin has a high affinity for HMG-CoA reductase and a longer half-life than some statins, enabling sustained enzyme inhibition and once-daily dosing. Clinical studies have robustly demonstrated atorvastatin's efficacy in reducing cardiovascular morbidity and mortality in diverse populations, supporting its widespread use in primary and secondary prevention of atherosclerotic cardiovascular disease.

Pharmacological Actions

Inhibition of HMG-CoA reductase leading to decreased cholesterol synthesis
Upregulation of hepatic LDL receptors resulting in increased clearance of LDL cholesterol
Reduction of plasma LDL cholesterol, total cholesterol, and apolipoprotein B levels
Moderate reduction of triglyceride levels
Modest elevation of high-density lipoprotein (HDL) cholesterol
Improvement of endothelial function and nitric oxide bioavailability
Anti-inflammatory effects within the vascular endothelium
Stabilization of atherosclerotic plaques reducing risk of rupture
Reduction of oxidative stress mediators in cardiovascular tissues
Inhibition of platelet aggregation and thrombus formation
Contribution to the regression or retardation of atherosclerosis progression
Potential beneficial effects on vascular remodeling
Possible attenuation of inflammatory cytokines and adhesion molecules
Pleiotropic cardiovascular protective effects beyond lipid lowering

Therapeutic Or Clinical Uses

Treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial)
Management of mixed dyslipidemia (elevated LDL and triglycerides)
Reduction of elevated total cholesterol and triglycerides in patients with hyperlipidemia
Prevention of cardiovascular disease including myocardial infarction and stroke in patients with risk factors
Secondary prevention of recurrent cardiovascular events post myocardial infarction or stroke
Treatment of familial heterozygous hypercholesterolemia in children and adolescents aged 10-17 years
Reduction of coronary heart disease events in patients with established atherosclerotic disease
Adjunct to diet, exercise, and weight control in managing lipid disorders
Management of elevated LDL cholesterol in patients at high risk of cardiovascular disease
Reduction of the need for coronary revascularization procedures
Use in polygenic hypercholesterolemia with or without elevated triglycerides
Adjunct therapy in patients with type 2 diabetes mellitus to reduce cardiovascular risk
Use in patients with metabolic syndrome-associated dyslipidemia
Management of lipid disorders when dietary modifications are insufficient

Side Or Adverse Effects

Myalgia (muscle pain, tenderness, or weakness)
Elevations in liver transaminases (ALT and AST), indicating possible hepatic injury
Rare incidence of rhabdomyolysis leading to acute kidney injury
Gastrointestinal disturbances including dyspepsia, diarrhea, and nausea
Headache and dizziness
Elevated blood glucose and risk of new-onset diabetes mellitus
Nasopharyngitis, upper respiratory tract infections, sore throat
Insomnia and sleep disturbances
Muscle spasms and cramps
Pain in extremities including arms and legs
Rare cases of hypersensitivity reactions such as rash or pruritus
Peripheral neuropathy reported in isolated cases
Elevated creatine kinase levels without symptoms
Possible cognitive effects such as memory loss or confusion (rare and reversible)
Allergic reactions including angioedema and anaphylaxis (very rare)

Precautions

Obtain baseline liver function tests prior to initiating therapy and periodically thereafter
Use caution in patients with a history of liver disease or elevated liver enzymes
Monitor for signs and symptoms of muscle toxicity, especially in elderly patients or those on interacting medications
Assess risk factors for diabetes mellitus before and during treatment
Avoid concurrent use with strong CYP3A4 inhibitors that may increase atorvastatin levels
Advise patients to report unexplained muscle pain, tenderness, or weakness promptly
Use caution in patients with hypothyroidism as it increases risk for myopathy
Limit alcohol intake to reduce risk of hepatotoxicity
Discontinue therapy if transaminase levels rise greater than three times the upper limit of normal
Evaluate renal function in patients with preexisting kidney disease prior to and during therapy
Pregnancy contraindicated due to potential teratogenic effects; ensure reliable contraception in women of childbearing potential
Assess potential drug interactions thoroughly before initiating atorvastatin
Educate patients about adherence to cholesterol-lowering diet and lifestyle modifications
Use caution when coadministered with other lipid-lowering agents
Regularly monitor lipid profiles and clinical response to adjust dosage appropriately

Warnings

Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases
Risk of severe muscle toxicity including rhabdomyolysis, which can lead to acute renal failure
Promptly discontinue therapy if signs of myopathy or rhabdomyolysis appear
Patients with predisposing factors such as advanced age, renal impairment, or interacting drugs are at higher risk for muscle toxicity
Avoid in pregnancy and lactation due to potential harm to the fetus and infant
May cause elevations in blood sugar; monitor patients at risk for diabetes
Grapefruit and grapefruit juice can increase atorvastatin blood levels and risk of adverse effects; avoid consumption during therapy
Use with caution in patients with heavy alcohol use or history of liver disease
Serious hypersensitivity reactions, including anaphylaxis and severe skin reactions, have been reported
Ensure patients are not taking medications that strongly inhibit CYP3A4 without medical supervision
Not recommended for use in pediatric patients under 10 years due to insufficient safety data
Post-marketing reports indicate potential for cognitive adverse events
Patients with multisystem disease may be at elevated risk for adverse muscle effects
Liver function monitoring is advised due to potential hepatotoxicity

Contraindication

Known hypersensitivity to atorvastatin or any component of the formulation
Active liver disease or unexplained persistent elevations of hepatic transaminase levels
Pregnancy due to potential teratogenic and fetotoxic effects
Lactation as the drug is excreted in human milk and may harm nursing infants
Concurrent use of strong CYP3A4 inhibitors without appropriate monitoring or dose adjustment
Patients with a history of atorvastatin-induced myopathy or rhabdomyolysis
Severe renal impairment in certain cases due to increased risk of adverse effects
Known hypersensitivity or allergy to other statins that may predispose to cross-reactivity
Active muscle disease or elevated creatine kinase levels without a known cause
Use in combination with specific interacting lipid-lowering agents contraindicated due to increased toxicity risk

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, posaconazole, voriconazole) increase atorvastatin plasma levels, enhancing risk of toxicity
Macrolide antibiotics such as erythromycin and clarithromycin can increase atorvastatin concentrations
Fibrates (gemfibrozil, fenofibrate, fenofibric acid) and niacin increase risk of myopathy when combined with atorvastatin
Colchicine coadministration increases risk of muscle toxicity
Immunosuppressants such as cyclosporine may elevate atorvastatin levels and toxicity risk
Antiviral agents for hepatitis C and HIV can interact by inhibiting CYP3A4
Birth control pills may have altered metabolism affecting efficacy and safety
Grapefruit juice can significantly elevate atorvastatin blood levels via CYP3A4 inhibition
Certain calcium channel blockers may increase atorvastatin exposure
Warfarin coadministration requires close monitoring due to potential increased bleeding risk
Drugs altering transporter proteins like OATP1B1 can affect atorvastatin disposition
Interactions with other lipid-lowering agents may increase adverse effect risks
Herbal supplements such as St. John's Wort may reduce atorvastatin efficacy by inducing CYP3A4
Concomitant use of multiple interacting drugs can compound risk of hepatic and muscle toxicity
Dose adjustments and clinical monitoring are recommended when using atorvastatin with interacting medications

Preparations Of The Drug

Lipitor oral tablets in strengths of 10 mg, 20 mg, 40 mg, and 80 mg
Active ingredient: atorvastatin calcium
Inactive ingredients include calcium carbonate, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and coating agents such as hypromellose, polyethylene glycol, talc, titanium dioxide
Formulated for oral administration with film coating for stability and ease of swallowing
Packaged in blister packs or bottles for prescription dispensing
Pharmaceutical-grade calcium salt of atorvastatin to enhance solubility and bioavailability
Manufactured under Good Manufacturing Practices standards by Pfizer Inc.
Includes patient information leaflets detailing dosage instructions and safety information
Available as generic atorvastatin calcium tablets in identical strengths
Stored at room temperature, protected from moisture, heat, and light
Prepared with excipients ensuring sustained shelf life and consistent dosing
Coating ensures minimal taste and protects drug from degradation
Batch quality control ensures uniform potency and purity
Distribution including lot tracing and expiration control for safety
Provision of dosing guidelines and support materials for healthcare providers